Melanoma & Skin Cancer | Specialty

Bristol-Myers Squibb Challenges Patent on Merck's Pembrolizumab

September 5th 2014

BMS has filed a lawsuit over Merck's newly approved immunotherapy drug pembrolizumab, contending that the much-heralded PD-1 inhibitor will infringe upon patents that Bristol-Myers holds on the groundbreaking technology.

FDA Approves Pembrolizumab for Advanced Melanoma

September 4th 2014

The FDA has approved pembrolizumab (Keytruda) as a treatment for patients with advanced or unresectable melanoma who are no longer responding to other drugs, making it the first PD-1 inhibitor to gain approval in the United States.

Patient-Derived Xenograft (PDX) Models as Avatars for Patient Response to Therapy

September 3rd 2014

The promise of personalized medicine in cancer will only be met once physicians have both the arsenal of therapeutics they need and a more complete understanding of genomic tumor profiles.

Update on Vismodegib's Place in the Treatment of Advanced BCC

August 18th 2014

Basal cell carcinoma (BCC) is the most common human malignancy and by far the most prevalent form of skin cancer, accounting for more than 80% of all cases.

Dr. Daniels Discusses the Findings of the 2007-2012 PROCLAIM National Registry

August 7th 2014

Gregory A. Daniels, MD, PhD, Associate Clinical Professor of Medicine, Division of Hematology-Oncology, University of California, San Diego, discusses the findings of the 2007-2012 PROCLAIM national registry

Immunotherapy Advances in Melanoma

July 28th 2014

Melanoma care has fortunately undergone a whirlwind of changes over the past several years. Novel immunotherapies are perhaps the most exciting recent development in cancer care because patients can enjoy long-term benefit from these treatments, meaning that they are possibly "cured."

Dr. Clarke on Melanoma Biopsies

July 25th 2014

Loren Clarke, MD, vice president of Medical Affairs of Dermatology at Myriad Genetics, discusses melanoma biopsies.

Dabrafenib/Trametinib Extends OS Versus Vemurafenib in Phase III Melanoma Trial

July 18th 2014

A phase III study comparing trametinib (Mekinist) plus dabrafenib (Tafinlar) with single-agent vemurafenib (Zelboraf) has been stopped early following a positive interim analysis

Immunotherapy Branches Out

July 18th 2014

Immunotherapy agents are delivering impressive results in a broad range of tumor types, reinforcing the excitement in research and investment circles for anticancer strategies that actively harness the immune system

Vemurafenib/Cobimetinib Extends PFS in Phase III Melanoma Study

July 14th 2014

The combination of the BRAF inhibitor vemurafenib and the MEK inhibitor cobimetinib significantly improved PFS compared with vemurafenib alone for patients with untreated BRAFV600-mutated advanced melanoma.

Dr. Puzanov on T-VEC in Combination with Ipilimumab for Melanoma Treatment

July 9th 2014

Igor Puzanov, MD, medical oncologist, Vanderbilt-Ingram Cancer Center, discusses the rationale behind a phase Ib study to evaluate the efficacy and safety of T-VEC and ipilimumab in previously untreated, unresected stage IIIB-IV melanoma.

Nivolumab, Alectinib Gain Approvals in Japan

July 7th 2014

The PD-1 inhibitor nivolumab and the second-generation ALK inhibitor alectinib have each gained their first approvals as treatments for patients in Japan.

Frontline Nivolumab Improves Survival in Phase III Melanoma Study

June 25th 2014

Frontline treatment with the anti-PD-1 agent nivolumab significantly extended overall survival when compared with dacarbazine for patients with metastatic or unresectable melanoma.

Conclusion: Improving Outcomes in Melanoma

June 17th 2014

Surgery Following Systemic Therapy in Melanoma

June 17th 2014

Nivolumab Plus Ipilimumab in Advanced Melanoma

June 17th 2014

Immunotherapy Combinations in Advanced Melanoma

June 17th 2014

Novel Therapies in Metastatic Melanoma

June 17th 2014

Strategies for the Detection of Recurrent Melanoma

June 17th 2014

Ipilimumab Side Effect Management in Melanoma

June 17th 2014